New cell therapy combo tested for Tough-to-Treat blood cancer
NCT ID NCT06768476
Summary
This is an early-phase safety study testing a new combination treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to standard therapies. The treatment involves a single infusion of genetically modified immune cells (CART123) given after a short course of the drug ruxolitinib. The main goal is to see if this combination is safe and feasible for patients who have very limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.